Information on Natalizumab (marketed as Tysabri)
Links shared publicly online about this topic.
- 1,744total visits
Information on Natalizumab (marketed as Tysabri)
fda.gov —
View full resource at fda.gov
Tags: Tysabri
Most Recently Shared on September 17, 2009 at 11:17 am By:
RT @FDA_Drug_Info: New Safety Information: Tysabri (natalizumab). http://bit.ly/tysabri
Also Shared By:
TYSABRI? Ongoing Research
msrc.co.uk — “Tysabri (Natalizumab) page with information on Tysabri (Natalizumab) and Multiple Sclerosis Research in the MS Research News section of the Multiple Sclerosis Resource Centre (MSRC) website.” View full resource at msrc.co.uk
Most Recently Shared on October 22, 2011 at 8:31 pm By:
@jcberrypdx Press releases re: Tysabri Research can be found at MSRC http://t.co/Py15QLcT (in addition to the link below re: tysabri news)
TYSABRI?
msrc.co.uk — “Tysabri (Natalizumab) Latest News page with information on the latest Tysabri (Natalizumab) news and Multiple Sclerosis Research in the MS Research News section of the Multiple Sclerosis Resource Centre (MSRC) website.” View full resource at msrc.co.uk
Most Recently Shared on October 22, 2011 at 8:25 pm By:
@jcberrypdx Or per 1000: 2.41 (1 yr or longer), 3.03 (2 yrs or longer), 1.85 (3 yrs or longer) http://t.co/CTbizWd7 scroll down to July
FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on April 23, 2011 at 11:06 pm By:
FDA Alert - Update of Healthcare Professional Information: Tysabri (natalizumab) - http://bit.ly/dV3ExV
MS Newsmakers Series: Tysabri 6-Years On - Multiple Sclerosis Blog
everydayhealth.com — “As one new oral therapy drug for MS makes its way to the world market and another, Cladribine Novaplus (Cladribine), stumbles in approval proceedings, many of our readers still have questions about Tysabri (Natalizumab).” View full resource at everydayhealth.com
Most Recently Shared on October 22, 2010 at 12:39 am By:
MS Blog Update: MS Newsmakers Series: Tysabri 6-Years On - As one new oral therapy drug for MS makes its way to the ... http://ht.ly/19zB5G
FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on February 7, 2010 at 10:06 pm By:
FDA Alert - Revisions to Prescribing Information for Tysabri (natalizumab) - http://bit.ly/b2C46Z
Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy - MPR
empr.com — “The FDA has notified healthcare professionals and patients that the risk of developing progressive multifocal leukoencephalopathy (PML) increases with the number of Tysabri (natalizumab, from Biogen Idec) infusions received.” View full resource at empr.com
Most Recently Shared on February 5, 2010 at 6:44 pm By:
MPR News: Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy: Th... http://bit.ly/9G7EQr
Tysabri (Natalizumab): Update of Healthcare Professional Information
fda.gov — “Risk of developing progressive multifocal leukoencephalopathy (PML) increases with increasing duration of exposure to Tysabri.” View full resource at fda.gov
Most Recently Shared on February 5, 2010 at 4:43 pm By:
eyeonfda Pharma and Health Lawyer
FDA MedWatch updates on Tysabri - http://ow.ly/14hlb - PML Risk increases with number of infusions.
FDA Alert: Natalizumab (marketed as Tysabri)
drugs.com — “FDA Alert: Natalizumab (marketed as Tysabri)” View full resource at drugs.com
Most Recently Shared on September 18, 2009 at 2:16 am By:
FDA Alert - FDA Reports PML Cases in Tysabri (natalizumab) Patients - http://bit.ly/tvthZ
Advertisement
Gannett Healthcare
@Nurse_com
FDA receives reports of PML in patients receiving Tysabri: http://bit.ly/SD3Nr
1 year ago...